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Objectives 
 
Review bibliographical data on Drug-Induced Thrombocytopenia (DITP), a potentially 
serious adverse event caused by some medications. The main aim is to elucidate what is 
DITP, its causing mechanims, its diagnostic criteria and the prevalence of DITP since 2010. 
 
Methods 
 
Compiled data have been reviewed from databases such as Pubmed, Medline 
and ScienceDirect using the keywords ‘Thrombocytopenia/DITP’. The results of 
the search were further matched with information provided from the University of 
Oklahoma website focused on platelet disorders[4]. 
 
 
DITP can be caused by several immune or non-immune mechanisms 
 
!  Non-immune DITP: megakaryocyte proliferation impairment  
!  Immune-mediated DITP platelet destruction due to drug-dependent platelet-antibodies. 
It can be caused by certain foods and beverages 
In some cases, DITP can be mistaken for other 
immune reactions such as ITP. Immune 
Thrombocytopenic Purpura (ITP) is due to the 
presence of autoantibodies against platelet GPs. 
Moreover, platelet GPs have polymorphisms that 
can induce alloantibody appearance after 
pregnancy or platelet transfusions. 
 
So, DITP laboratory tests result comparable to 
these immune reactions that cause 
thrombocytopenia because they only 
demonstrate the presence of antibodies against 
platelets, but not their cause. 
e) Mechanism of autoantibody formation 
Mechanisms proposed to explain immune-mediated DITP: 
Prevalence research 
 
"  126 clinical cases concerning 69 different drugs or chemicals causing DITP, including food 
and beverages, have been reported since 2010. 
"  Results are summarized in the next table and figures: 
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Diagnostic criteria 
"  A systematic clinical history is essential in 
establishing the diagnosis of DITP, (exposure 
to drugs, herbal preparations, certain foods 
and beverages) 
"  Differential diagnosis with ITP is important for 
the patient’s treatment 
"  Clinical criteria have been established to 
determine the likelihood of a drug being the 
cause DITP (definite, probable, possible and 
unlikely according to the criteria stipulated) 
"  Laboratory Tests: drug-dependent platelet-
antibodies can be detected in the patient 
serum,  by different  in vitro techniques using 
flow cytometry. 
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Conclusions 
 
"  It is difficult to know the real incidence of 
DITP 
"   Limited number of published reports of 
DITP for the last five years 
"  There is a need to established uniform 
methods to improve the reproducibility of 
results to enable reliable comparisons. 
"  There is a need to report new cases in a 
single central database useful as a 
global reference for the correct 
diagnostic and the most suitable 
treatment of DITP.  
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Background 
Platelets are anucleated cells produced in the bone 
marrow from megakaryocytes, circulate 7-10 days in 
peripheral blood (150.000–450.000/µL) and then are 
destroyed in the spleen and liver. They play a very 
important role in haemostasis making blood clot and 
help stop bleeding. 
 
Platelets contain several types of glycoproteins in 
their membrane expressing a set of antigens (Figure 
2). These antigens can be recognized by auto-
antibodies or alloantibodies, increasing platelet 
destruction.   
Thrombocytopenia is a persistent decrease in the 
number of blood platelets <100.000/µL. 
 
According to its pathophysiology, thrombocytopenia can 
be classified as caused by:   
 
!  a decrease in the platelet production 
!  an increase in the destruction of platelets 
! sequestration in the spleen 
!  Haemodilution"
 
Figure 1: Haematopoiesis in bone marrow. 
Figure 2:Main GPs complexes present on the platelet 
surface[1].  
Figure 8: Graphic data of the % of reported drugs causing DITP 
since 2010[4].   
Figure 9: Histogram showing the number of cases 
reported for every drug found in the search since 2010[4]. 
Figura 10: Positive and negative results from a cytometry flow 
laboratory test to demonstrate the presence of antibodies in 
the serum of patients with DITP[3].   
a) Mechanism of Adsorption b) Mechanism of immune-complexes 
c) Mechanism of haptens d) Mechanism of fibans 
If it becomes sever, cutaneous bleeding, epistaxis, gingival bleeding, hematuria, or other 
hemorrhagic complications can occur 
Figure 3: Mechanism of adsorption. The drug is 
adsorbed, binds to platelet GPs  and drug-
dependent antibodies react with cells[2]. 
Figure 4: Mechanism of immune-complexes. The 
drug induces the synthesis of antibodies specific for 
them and then both antibody and drug can be joined 
to form an immune complex capable of reacting with 
platelets[2].  
Figure 5: Mechanism of hapten-induced antibodies. 
Drug molecules are too small to be immunogenic, but 
when they bind to platelets, they formed a hapten-
platelet complex that induces the production of 
specific hapten antibodies[2]. 
Figure 6: Mechanism of fibans. Fibans bind platelet 
GPs and change their conformation, inducing the 
emergence of neoepitopes, which become the 
target of antibodies[2]. 
 
Figure 6: Mechanism of auto-antibodies formation. The drug induce 
the formation of drug-independent platelet autoantibodies that bind to 
platelet antigens even in the absence of the drug. The resultant 
thrombocytopenia can persist after the drug is discontinued[2].  
